JOHN E CAMPBELL
Broker in Newton, MA
License number
Massachusetts 9010820
Issued Date
Jan 18, 1995
Expiration Date
Apr 17, 1997
Type
Salesperson
Address
Address
Newton, MA 02459
Professional information
Cycloalkylamines As Monoamine Reuptake Inhibitors
US Patent:
2007020, Aug 30, 2007
Filed:
Jan 5, 2007
Appl. No.:
11/649927
Inventors:
Liming Shao - Lincoln MA, US
Fengjiang Wang - Northborough MA, US
Scott Malcolm - Southborough MA, US
Michael Hewitt - Somerville MA, US
Larry Bush - Worcester MA, US
Jianguo Ma - Natick MA, US
Mark Varney - Laguna Niguel CA, US
Una Campbell - Marlborough MA, US
Sharon Engel - Hudson MA, US
Larry Hardy - Sturbridge MA, US
Patrick Koch - Marlborough MA, US
John Campbell - Waban MA, US
Fengjiang Wang - Northborough MA, US
Scott Malcolm - Southborough MA, US
Michael Hewitt - Somerville MA, US
Larry Bush - Worcester MA, US
Jianguo Ma - Natick MA, US
Mark Varney - Laguna Niguel CA, US
Una Campbell - Marlborough MA, US
Sharon Engel - Hudson MA, US
Larry Hardy - Sturbridge MA, US
Patrick Koch - Marlborough MA, US
John Campbell - Waban MA, US
Assignee:
SEPRACOR INC. - Marlborough MA
International Classification:
A61K 31/55, A61K 31/445, A61K 31/40, A61K 31/397, A61K 31/396, C07D 211/06, C07D 203/04, C07D 207/04
US Classification:
514183000, 514212010, 514319000, 514408000, 548577000, 546205000, 540484000, 514210010, 548950000, 548954000
Abstract:
The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
Cycloalkylamines As Monoamine Reuptake Inhibitors
US Patent:
2010019, Jul 29, 2010
Filed:
Jan 15, 2010
Appl. No.:
12/688474
Inventors:
Liming Shao - Lincoln MA, US
Fengjiang Wang - Northborough MA, US
Scott Christopher Malcolm - Southborough MA, US
Michael Charles Hewitt - Somerville MA, US
Larry R. Bush - Worcester MA, US
Jianguo Ma - Natick MA, US
Mark A. Varney - Laguna Nigel CA, US
Una Campbell - Marlborough MA, US
Sharon Rae Engel - Hudson MA, US
Larry Wendell Hardy - Sturbridge MA, US
Patrick Koch - Marlborough MA, US
John E. Campbell - Waban MA, US
Fengjiang Wang - Northborough MA, US
Scott Christopher Malcolm - Southborough MA, US
Michael Charles Hewitt - Somerville MA, US
Larry R. Bush - Worcester MA, US
Jianguo Ma - Natick MA, US
Mark A. Varney - Laguna Nigel CA, US
Una Campbell - Marlborough MA, US
Sharon Rae Engel - Hudson MA, US
Larry Wendell Hardy - Sturbridge MA, US
Patrick Koch - Marlborough MA, US
John E. Campbell - Waban MA, US
International Classification:
A61K 31/135, C07C 211/15, C07C 215/48, A61P 25/00, A61P 25/24
US Classification:
514646, 564442, 564443
Abstract:
The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.